Cargando…

In Vitro Drug Repurposing: Focus on Vasodilators

Drug repurposing aims to identify new therapeutic uses for drugs that have already been approved for other conditions. This approach can save time and resources compared to traditional drug development, as the safety and efficacy of the repurposed drug have already been established. In the context o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro, Eduarda, Costa, Bárbara, Vasques-Nóvoa, Francisco, Vale, Nuno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954697/
https://www.ncbi.nlm.nih.gov/pubmed/36831338
http://dx.doi.org/10.3390/cells12040671
_version_ 1784894180692066304
author Ribeiro, Eduarda
Costa, Bárbara
Vasques-Nóvoa, Francisco
Vale, Nuno
author_facet Ribeiro, Eduarda
Costa, Bárbara
Vasques-Nóvoa, Francisco
Vale, Nuno
author_sort Ribeiro, Eduarda
collection PubMed
description Drug repurposing aims to identify new therapeutic uses for drugs that have already been approved for other conditions. This approach can save time and resources compared to traditional drug development, as the safety and efficacy of the repurposed drug have already been established. In the context of cancer, drug repurposing can lead to the discovery of new treatments that can target specific cancer cell lines and improve patient outcomes. Vasodilators are a class of drugs that have been shown to have the potential to influence various types of cancer. These medications work by relaxing the smooth muscle of blood vessels, increasing blood flow to tumors, and improving the delivery of chemotherapy drugs. Additionally, vasodilators have been found to have antiproliferative and proapoptotic effects on cancer cells, making them a promising target for drug repurposing. Research on vasodilators for cancer treatment has already shown promising results in preclinical and clinical studies. However, additionally research is needed to fully understand the mechanisms of action of vasodilators in cancer and determine the optimal dosing and combination therapy for patients. In this review, we aim to explore the molecular mechanisms of action of vasodilators in cancer cell lines and the current state of research on their repurposing as a treatment option. With the goal of minimizing the effort and resources required for traditional drug development, we hope to shed light on the potential of vasodilators as a viable therapeutic strategy for cancer patients.
format Online
Article
Text
id pubmed-9954697
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99546972023-02-25 In Vitro Drug Repurposing: Focus on Vasodilators Ribeiro, Eduarda Costa, Bárbara Vasques-Nóvoa, Francisco Vale, Nuno Cells Review Drug repurposing aims to identify new therapeutic uses for drugs that have already been approved for other conditions. This approach can save time and resources compared to traditional drug development, as the safety and efficacy of the repurposed drug have already been established. In the context of cancer, drug repurposing can lead to the discovery of new treatments that can target specific cancer cell lines and improve patient outcomes. Vasodilators are a class of drugs that have been shown to have the potential to influence various types of cancer. These medications work by relaxing the smooth muscle of blood vessels, increasing blood flow to tumors, and improving the delivery of chemotherapy drugs. Additionally, vasodilators have been found to have antiproliferative and proapoptotic effects on cancer cells, making them a promising target for drug repurposing. Research on vasodilators for cancer treatment has already shown promising results in preclinical and clinical studies. However, additionally research is needed to fully understand the mechanisms of action of vasodilators in cancer and determine the optimal dosing and combination therapy for patients. In this review, we aim to explore the molecular mechanisms of action of vasodilators in cancer cell lines and the current state of research on their repurposing as a treatment option. With the goal of minimizing the effort and resources required for traditional drug development, we hope to shed light on the potential of vasodilators as a viable therapeutic strategy for cancer patients. MDPI 2023-02-20 /pmc/articles/PMC9954697/ /pubmed/36831338 http://dx.doi.org/10.3390/cells12040671 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ribeiro, Eduarda
Costa, Bárbara
Vasques-Nóvoa, Francisco
Vale, Nuno
In Vitro Drug Repurposing: Focus on Vasodilators
title In Vitro Drug Repurposing: Focus on Vasodilators
title_full In Vitro Drug Repurposing: Focus on Vasodilators
title_fullStr In Vitro Drug Repurposing: Focus on Vasodilators
title_full_unstemmed In Vitro Drug Repurposing: Focus on Vasodilators
title_short In Vitro Drug Repurposing: Focus on Vasodilators
title_sort in vitro drug repurposing: focus on vasodilators
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954697/
https://www.ncbi.nlm.nih.gov/pubmed/36831338
http://dx.doi.org/10.3390/cells12040671
work_keys_str_mv AT ribeiroeduarda invitrodrugrepurposingfocusonvasodilators
AT costabarbara invitrodrugrepurposingfocusonvasodilators
AT vasquesnovoafrancisco invitrodrugrepurposingfocusonvasodilators
AT valenuno invitrodrugrepurposingfocusonvasodilators